Edition:
United States

Novus Therapeutics Inc (NVUS.OQ)

NVUS.OQ on NASDAQ Stock Exchange Capital Market

6.93USD
20 Jul 2018
Change (% chg)

$0.42 (+6.45%)
Prev Close
$6.51
Open
$6.55
Day's High
$6.93
Day's Low
$6.55
Volume
713
Avg. Vol
10,095
52-wk High
$8.61
52-wk Low
$3.13

Latest Key Developments (Source: Significant Developments)

Novus Therapeutics Reports Q4 Loss Per Share $0.30
Monday, 2 Apr 2018 09:00am EDT 

April 2 (Reuters) - Novus Therapeutics Inc ::YEAR 2017 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q4 LOSS PER SHARE $0.30.  Full Article

Andrew I. Mcdonald Reports 12.24 pct Passive Stake In Novus Therapeutics As Of March 9
Tuesday, 13 Mar 2018 12:17pm EDT 

March 13 (Reuters) - Novus Therapeutics Inc ::ANDREW I. MCDONALD REPORTS 12.24 PERCENT PASSIVE STAKE IN NOVUS THERAPEUTICS INC AS OF MARCH 9, 2018 - SEC FILING‍​.  Full Article

Novus Therapeutics Inc reported Q3 $0.43 loss per share​
Wednesday, 8 Nov 2017 05:17pm EST 

Nov 8 (Reuters) - Novus Therapeutics Inc :Novus Therapeutics Inc - ‍for Q3 of 2017, Novus reported $0.43 loss per share​.  Full Article

Novus Therapeutics reports third quarter 2017 results
Wednesday, 8 Nov 2017 04:53pm EST 

Nov 8 (Reuters) - Novus Therapeutics Inc :Novus Therapeutics reports third quarter 2017 results.Q3 loss per share $0.43.  Full Article

Novus Therapeutics reports Q2 loss per share $1.32
Wednesday, 9 Aug 2017 08:15pm EDT 

Aug 10 (Reuters) - Novus Therapeutics Inc -:Novus Therapeutics reports second quarter 2017 results.Q2 loss per share $1.32.  Full Article

Ran Nussbaum reports 11.3 pct passive stake in Novus Therapeutics as of May 9
Thursday, 25 May 2017 05:38pm EDT 

May 25 (Reuters) - Novus Therapeutics Inc :Ran nussbaum reports 11.3 percent passive stake in novus therapeutics inc as of may 9, 2017 - sec filing.  Full Article

Peregrine Ventures Management reports 8.9 percent passiave stake in Novus Therapeutics as of May 9
Monday, 22 May 2017 02:53pm EDT 

May 22 (Reuters) - Peregrine Ventures Management Ltd :Peregrine Ventures Management Ltd reports a 8.9 percent passiave stake in Novus Therapeutics Inc as of May 9, 2017 - sec filing.  Full Article

Tokai pharmaceuticals inc says under terms of deal co may be required to pay Otic termination fee of $1 million
Thursday, 22 Dec 2016 09:42am EST 

Tokai Pharmaceuticals Inc :Tokai Pharmaceuticals Inc says co may be required to pay Otic a termination fee of $1 million, or Otic may be required to pay co termination fee of $1.5 million.  Full Article

Tokai Pharmaceuticals and Otic Pharma enter into share purchase deal
Thursday, 22 Dec 2016 08:00am EST 

Tokai Pharmaceuticals Inc : Tokai Pharmaceuticals and Otic Pharma enter into share purchase agreement . Tokai Pharmaceuticals Inc says upon exchange, it is expected that existing tokai stockholders will own approximately 40% of combined company . Tokai Pharmaceuticals - entered into a definitive share purchase agreement under which shareholders of otic pharma will become majority owners of tokai . Tokai Pharmaceuticals Inc - gregory j. Flesher to be named president and chief executive officer of combined company . Tokai Pharmaceuticals Inc - shareholders of otic pharma will receive a total of 32.2 million shares of newly issued tokai common stock . Transaction has been unanimously approved by boards of directors of both companies and shareholders of otic pharma . Tokai Pharmaceuticals Inc says existing otic pharma shareholders owning approximately 60% of combined company . Tokai Pharmaceuticals - upon close of transaction, board of combined cowill consist of 7 members, 3 to be designated by tokai, 4 to be designated by otic pharma .Tokai Pharmaceuticals - an otic pharma investor syndicate has committed to invest $7 million of additional capital in connection with share purchase agreement.  Full Article

Tokai Pharmaceuticals appoints John S. Mcbride CFO
Wednesday, 3 Aug 2016 07:54am EDT 

Tokai Pharmaceuticals Inc : Lee H. Kalowski, chief financial officer will cease employment effective august 31, 2016 - SEC filing . CFO, EVP, business operations and general counsel, will cease employment in relation to previously announced workforce reduction . Previously announced retirement of Karen J. Ferrante, chief medical officer, will become effective on august 31, 2016 .Appointed John S. Mcbride chief financial officer effective September 1, 2016.  Full Article